For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| General and administrative | 1,934,324 | 7,754,447.5* | 1,752,262 | 1,662,223 |
| Realized foreign currency translation loss from dissolution of subsidiaries | - | - | - | 0 |
| Research and development | 2,942,320 | 2,721,416.5* | 1,357,793 | 2,148,676 |
| Foreign currency gain | - | - | - | 29,290 |
| Loss from operations | -4,876,644 | -10,475,864* | -3,110,055 | -3,810,899 |
| Change in fair value of warrant liabilities | -1,542,132 | -57,650* | -46,870 | 8,436 |
| Realized foreign currency translation loss from dissolution of subsidiaries | - | -1,792.75* | - | - |
| Foreign currency (loss) gain | -9,491 | 109,126* | -26,250 | - |
| Other income | 24,183 | -62,745* | 8,619 | 19,464 |
| Change in fair value of derivative warrant liability | - | 104,154.75* | - | - |
| Interest and dividends, net | 450,338 | 180,463* | 43,396 | 54,424 |
| Other income, net | 2,007,162 | 178,546.5* | 72,635 | 94,742 |
| Loss before income taxes | -2,869,482 | -10,297,317.5 | -3,037,420 | -3,716,157 |
| Provision for income taxes | - | - | - | 0 |
| Segment and consolidated net loss | -2,869,482 | -10,297,317.5* | -3,037,420 | -3,716,157 |
| Foreign currency translation | 28,132 | -17,132* | 18,301 | 5,631 |
| Comprehensive loss | -2,841,350 | -10,314,449.5 | -3,019,119 | -3,710,526 |
| Basic EPS | -0.12 | -1.288 | -0.41 | -0.66 |
| Diluted EPS | -0.12 | -1.288 | -0.41 | -0.66 |
| Basic Average Shares | 24,337,812 | 8,008,322 | 7,443,577 | 5,641,251 |
| Diluted Average Shares | 24,337,812 | 8,008,322 | 7,443,577 | 5,641,251 |
Pasithea Therapeutics Corp. (KTTA)
Pasithea Therapeutics Corp. (KTTA)